Pharmaceutical Technology

FEBRUARY 24, 2023

According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Amivantamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Roots Analysis

JANUARY 21, 2024

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

Pharma Packaging Solutions

JUNE 30, 2023

Biopharmaceuticals, also called biologics, are drug products that are manufactured using biological sources. Semi-Synthesized: Though the term “biologic” is accurate for the extracted materials listed above, it is more often used to describe therapeutics that are produced with recombinant DNA technology.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

Pharma Packaging Solutions

SEPTEMBER 22, 2023

Biologics are drug products that are manufactured using materials from living sources. There are a few common types of biologics, including extracted (taken directly from a living system), semi-synthesized (produced with recombinant DNA technology), vaccines, and gene therapies. Let’s talk about it. What are Biologics?

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Pharma Packaging 52

Cloudbyz

MARCH 6, 2024

Traditionally, pharmaceutical therapies have primarily consisted of small molecule drugs, commonly known as pills. This shift signifies not just a change in the way drugs are manufactured and administered, but also a fundamental transformation in the approach to treating diseases at their root cause.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials.

Genetic Engineering 52

Genetic Engineering Clinical Trials Clinical Trials Engineer 52

The Pharma Data

JULY 11, 2021

TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. No dedicated drug-drug interaction studies have been conducted. Treatment with lanadelumab has been associated with development of treatment emergent anti-drug antibodies (ADA) in 11.9% (10/84) of subjects. Interactions.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52